This event was sponsored by:
On 12 March 2014, Beltox organized the 3rd workshop on non-clinical safety assessment of biopharmaceuticals with a focus on next generation therapies. This time, the workshop was held at GSK Vaccines in Wavre. More than 60 participants from across Europe (i.e. Belgium, The Netherlands, UK, France, Italy and Finland) attended the meeting. In the morning, excellent high level scientific presentations from industry, contract organisations and regulatory bodies brought everyone up to speed on the current status and future challenges around the development of oligonucleotide and gene therapies. In the afternoon, the successful approach of case study discussion groups introduced at the 2nd workshop, was maintained. The audience was split into working groups, that analysed different cases of realistic issues in the development of biologicals. Thereafter, the outcome of each working group was presented to the entire audience and triggered interesting, very interactive discussions on the best strategies to resolve the issues raises. This workshop was made possible thanks to the valuable sponsoring from WIL Research Europe, Charles River, CitoxLab, Covance and TNO Triskelion. Beltox would like to thank the organizing committee for the excellent organisation, GSK Vaccines for the hospitality and all participants to the meeting for their active contribution. The positive feedback received from the participants is of course a strong stimulus for the organizing committee to already plan for the next workshop. This will probably take place in the fall of 2015. Looking forward to meeting many of you there !